However it is worth to underline that, although FGFR targeted therapies have been specifically developed to inhibit FGFR activation and downstream signalling cascade, currently in clinical practice the selection of iCCA patients candidate to these treatments only relies on the detection of FGFR2 GAs in the tumor tissue, without any information about the status of FGFR downstream signalling cascade. This evidence concerns the gene FGFR2 and infantile convulsions and choreoathetosis.